Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) - Net Assets
Based on the latest financial reports, Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) has net assets worth €7.52 Billion EUR (≈ $8.79 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€10.44 Billion ≈ $12.20 Billion USD) and total liabilities (€2.91 Billion ≈ $3.41 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Tianjin Zhong Xin Pharmaceutical Group C (2TZ) tangible net worth to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €7.52 Billion |
| % of Total Assets | 72.08% |
| Annual Growth Rate | 8.82% |
| 5-Year Change | 9.0% |
| 10-Year Change | 65.03% |
| Growth Volatility | 11.27 |
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited - Net Assets Trend (2013–2025)
This chart illustrates how Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's net assets have evolved over time, based on quarterly financial data. See 2TZ defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2013–2025)
The table below shows the annual net assets of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited from 2013 to 2025. For live valuation and market cap data, see Tianjin Zhong Xin Pharmaceutical Group C market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €7.10 Billion ≈ $8.30 Billion |
-9.55% |
| 2024-12-31 | €7.85 Billion ≈ $9.18 Billion |
+18.13% |
| 2023-12-31 | €6.65 Billion ≈ $7.77 Billion |
+1.42% |
| 2022-12-31 | €6.55 Billion ≈ $7.66 Billion |
+0.59% |
| 2021-12-31 | €6.51 Billion ≈ $7.62 Billion |
+9.48% |
| 2020-12-31 | €5.95 Billion ≈ $6.96 Billion |
+7.73% |
| 2019-12-31 | €5.52 Billion ≈ $6.46 Billion |
+9.28% |
| 2018-12-31 | €5.05 Billion ≈ $5.91 Billion |
+9.27% |
| 2017-12-31 | €4.63 Billion ≈ $5.41 Billion |
+7.51% |
| 2016-12-31 | €4.30 Billion ≈ $5.03 Billion |
+4.80% |
| 2015-12-31 | €4.11 Billion ≈ $4.80 Billion |
+39.32% |
| 2014-12-31 | €2.95 Billion ≈ $3.44 Billion |
+14.43% |
| 2013-12-31 | €2.57 Billion ≈ $3.01 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 337.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €4.89 Billion | 68.93% |
| Other Components | €2.21 Billion | 31.07% |
| Total Equity | €7.10 Billion | 100.00% |
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Competitors by Market Cap
The table below lists competitors of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bank of Kaohsiung Ltd
TW:2836
|
$692.23 Million |
|
Goldcard High-Tech Co Ltd
SHE:300349
|
$692.32 Million |
|
QITIAN Technology Group Co Ltd
SHE:300061
|
$692.38 Million |
|
Logistea AB Series B
ST:LOGI-B
|
$692.43 Million |
|
Diagnósticos da América S.A
SA:DASA3
|
$691.54 Million |
|
Cannae Holdings Inc
NYSE:CNNE
|
$691.40 Million |
|
Collins Foods Ltd
AU:CKF
|
$691.28 Million |
|
Sunyard System Engineering Co Ltd
SHG:600571
|
$691.24 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,843,592,379 to 7,099,497,153, a change of -744,095,226 (-9.5%).
- Net income of 2,131,021,537 contributed positively to equity growth.
- Dividend payments of 981,285,788 reduced retained earnings.
- Other factors decreased equity by 1,893,830,974.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €2.13 Billion | +30.02% |
| Dividends Paid | €981.29 Million | -13.82% |
| Other Changes | €-1.89 Billion | -26.68% |
| Total Change | €- | -9.49% |
Book Value vs Market Value Analysis
This analysis compares Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.17x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.51x to 0.17x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €5.82 | €2.96 | x |
| 2018-12-31 | €6.41 | €2.96 | x |
| 2019-12-31 | €7.01 | €2.96 | x |
| 2020-12-31 | €7.51 | €2.96 | x |
| 2021-12-31 | €8.23 | €2.96 | x |
| 2022-12-31 | €8.43 | €2.96 | x |
| 2023-12-31 | €16.50 | €2.96 | x |
| 2024-12-31 | €10.18 | €2.96 | x |
| 2025-12-31 | €17.75 | €2.96 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tianjin Zhong Xin Pharmaceutical Group Corporation Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 30.02%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 43.34%
- • Asset Turnover: 0.42x
- • Equity Multiplier: 1.65x
- Recent ROE (30.02%) is above the historical average (14.84%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 14.55% | 5.85% | 1.14x | 2.18x | €110.06 Million |
| 2014 | 12.95% | 5.05% | 1.30x | 1.97x | €81.42 Million |
| 2015 | 11.51% | 6.38% | 1.17x | 1.55x | €59.27 Million |
| 2016 | 10.20% | 6.84% | 0.97x | 1.54x | €8.46 Million |
| 2017 | 10.63% | 8.37% | 0.86x | 1.48x | €28.40 Million |
| 2018 | 11.40% | 8.83% | 0.89x | 1.44x | €68.98 Million |
| 2019 | 11.61% | 8.94% | 0.89x | 1.46x | €86.75 Million |
| 2020 | 11.39% | 10.02% | 0.80x | 1.43x | €80.86 Million |
| 2021 | 12.08% | 11.13% | 0.76x | 1.42x | €132.70 Million |
| 2022 | 13.21% | 10.45% | 0.81x | 1.56x | €209.65 Million |
| 2023 | 14.95% | 12.00% | 0.80x | 1.55x | €326.64 Million |
| 2024 | 28.42% | 30.51% | 0.68x | 1.37x | €1.44 Billion |
| 2025 | 30.02% | 43.34% | 0.42x | 1.65x | €1.42 Billion |
Industry Comparison
This section compares Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $5,422,281,612
- Average return on equity (ROE) among peers: -106.21%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | €7.52 Billion | 14.55% | 0.39x | $692.11 Million |
| SHANG.FOS.PHARM.GR.H YC 1 (08HH) | $48.38 Billion | 9.77% | 0.93x | $1.10 Billion |
| PEPTONIC MEDICAL (28L) | $75.32 Million | -56.54% | 0.42x | $4.14 Million |
| WEST ISLAND BRANDS INC. (39N0) | $3.27 Million | -157.21% | 0.88x | $1.34 Million |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $534.88K | -741.80% | 26.77x | $97.35K |
| CERENO SCIENTIFIC AB B (4A1) | $170.06 Million | -9.56% | 0.06x | $157.72 Million |
| MAPLE LEAF GREEN WORLD (4HV0) | $-8.51 Million | 0.00% | 0.00x | $504.30K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-815.79K | 0.00% | 0.00x | $134.78K |
| RED LIGHT HOLLAND CORP. (4YX) | $26.34 Million | -20.49% | 0.14x | $8.71 Million |
| EQL PHARMA AB (7JK) | $154.75 Million | 19.98% | 0.85x | $73.36 Million |
About Tianjin Zhong Xin Pharmaceutical Group Corporation Limited
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People's Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and… Read more